ストックスクリーナーアプリを入手
138.16
5.42%
-7.91
アフターアワーズ：
137.92
-0.24
-0.17%
前日終値:
$146.07
開ける：
$147.02
24時間の取引高:
193.33K
Relative Volume:
0.83
時価総額：
$1.99B
収益：
$1.30M
当期純損益:
$-49.30M
株価収益率:
-33.14
EPS:
-4.1688
ネットキャッシュフロー:
$-29.10M
1週間 パフォーマンス:
-8.24%
1か月 パフォーマンス:
-6.80%
6か月 パフォーマンス:
+14.76%
1年 パフォーマンス:
+139.49%
1日の値動き範囲:
$137.86
$147.44
1週間の範囲:
$137.86
$160.84
52週間の値動き範囲:
$58.16
$161.38
Palvella Therapeutics Inc Stock (PVLA) Company Profile
名前
Palvella Therapeutics Inc
セクター
電話
(484) 253-1461
住所
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
138.16 | 1.99B | 1.30M | -49.30M | -29.10M | -4.1688 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 開始されました | Mizuho | Outperform |
| 2025-12-05 | 開始されました | BTIG Research | Buy |
| 2025-12-04 | 開始されました | Craig Hallum | Buy |
| 2025-11-19 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | 開始されました | Oppenheimer | Outperform |
| 2025-08-06 | 開始されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-04-09 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-26 | 開始されました | Stifel | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-20 | 開始されました | Canaccord Genuity | Buy |
| 2025-02-05 | 開始されました | TD Cowen | Buy |
| 2024-12-26 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-03-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 開始されました | Robert W. Baird | Outperform |
| 2018-03-19 | 開始されました | Evercore ISI | Outperform |
| 2018-03-19 | 開始されました | Jefferies | Buy |
| 2018-01-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-05-30 | 開始されました | Rodman & Renshaw | Buy |
| 2016-08-05 | 再開されました | ROTH Capital | Buy |
| 2015-08-12 | 開始されました | JMP Securities | Mkt Outperform |
| 2015-07-27 | 開始されました | Oppenheimer | Outperform |
| 2015-07-22 | 開始されました | ROTH Capital | Buy |
すべてを表示
Palvella Therapeutics Inc (PVLA) 最新ニュース
Palvella Therapeutics Price Target Maintained With a $240.00/Share by Chardan Capital - Moomoo
Chardan Capital maintains Buy rating on Palvella Therapeutics, $240 price target - TradingView
Palvella Therapeutics (PVLA) COO sells 4,302 shares under 10b5-1 plan - Stock Titan
Palvella Therapeutics Q2 2026 Earnings: Wider-Than-Expected Loss as Pipeline Spending AcceleratesEarnings Growth Analysis - careplusvn.com
Palvella (NASDAQ: PVLA) officer plans new stock sale after three recent trades - Stock Titan
Palvella Therapeutics director George M Jenkins sells $4.17 million in shares By Investing.com - Investing.com South Africa
Palvella Therapeutics director George M Jenkins sells $4.17 million in shares - Investing.com UK
Director at Palvella Therapeutics (PVLA) sells 27,500 shares under trading plan - Stock Titan
Palvella Names James Treat CMO as QTORIN Advances Toward Market - mychesco.com
Director at Palvella Therapeutics (NASDAQ: PVLA) plans multi-million-dollar stock sale - Stock Titan
Palvella Therapeutics, Inc (NASDAQ: PVLA) Share Price, PVLA Stock News, PVLA Share Price & Updates - Kalkine
Mizuho Securities Keeps Their Buy Rating on Palvella Therapeutics (PVLA) - theglobeandmail.com
Palvella Therapeutics Names James Treat Chief Medical Officer Ahead of QTORIN Commercialization - citybiz
Palvella at Cantor global healthcare conference: rare-disease push By Investing.com - Investing.com India
Palvella Therapeutics Appoints James Treat, M.D., as Chief Medical Officer - Quiver Quantitative
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer - Yahoo Finance
KIRITSY CHRISTOPHER P Executes Palvella Therapeutics Options and Sells Shares at $157 on September 2, 2026 - Kalkine Media
Palvella CEO to Pitch Rare-Disease Pipeline at Investor Meets - MyChesCo
ICYMI: Palvella Seeks FDA Approval for Rare-Disease Skin Therapy - MyChesCo
Palvella Therapeutics (NASDAQ: PVLA) director exercises options, then sells 313 shares - Stock Titan
Palvella Therapeutics (NASDAQ: PVLA) investor to sell 375 shares - Stock Titan
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences - The Manila Times
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX) - The Globe and Mail
Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240 - Moomoo
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations - Barchart.com
Palvella Therapeutics Completes Rolling Submission of NDA for QTORIN Rapamycin - Yahoo Finance
Hsbc Holdings PLC Invests $7.64 Million in Palvella Therapeutics, Inc. $PVLA - MarketBeat
36,259 Shares in Palvella Therapeutics, Inc. $PVLA Purchased by Blue Owl Capital Holdings LP - MarketBeat
Palvella Therapeutics COO Kathleen Goin Executes Stock Option Exercises and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells $654,807.42 in Stock - MarketBeat
Palvella Therapeutics (NASDAQ: PVLA) COO sells 4,302 shares under 10b5-1 plan - Stock Titan
Palvella (PVLA) Latest Quarter: EPS Comes in Below Forecast in the Available Record; Share Response: Shares Fall 6.03% for the Current SessionConsensus Forecast Report - vinanet.vn
Lisanti Capital Growth LLC Purchases Shares of 42,975 Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics (NASDAQ: PVLA) officer plans $647K share sale - Stock Titan
Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel - Seeking Alpha
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands - MarketBeat
PRUDENTIAL FINANCIAL INC Establishes New Position in Palvella Th - GuruFocus
First Light Asset Management (PVLA) discloses 5.34% Palvella Therapeutics stake in client accounts - Stock Titan
Palvella at Canaccord Genuity’s 46th Annual Growth Conference: launch prep By Investing.com - Investing.com Canada
Palvella (PVLA) Q2 2026 Earnings Call Transcript - AOL.com
Prudential Financial (PVLA) reports 6.7% beneficial ownership in Palvella Therapeutics - Stock Titan
Palvella Therapeutics, Inc. (PVLA) stock price, news, quote and history - Yahoo Finance Australia
Palvella Therapeutics, Inc. (PVLA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Palvella Therapeutics, Inc. $PVLA Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval? - Yahoo Finance
Jennison Associates Expands Palvella Therapeutics (PVLA) Stake i - GuruFocus
Palvella Therapeutics Inc (PVLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Q3 EPS Estimate for Palvella Therapeutics Cut by Analyst - marketbeat.com
Truist Financial Sticks to Its Buy Rating for Palvella Therapeutics (PVLA) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Palvella Therapeutics Inc (PVLA) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):